Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Roland Berger Dapu: China's Supply Chain Advantages Are Difficult to Replace
Ask AI · How can China’s supply chain advantages continue to evolve through innovation?
China’s supply chain, with its highly integrated system, mature industrial clusters, and proven high efficiency, still holds irreplaceable competitive advantages, according to Patuo Dai, Co-CEO of Roland Berger Global Management Committee, who recently spoke in Beijing.
The China Development Forum 2026 Annual Meeting was held from March 22 to 23. During an exclusive interview with China News Service, Dai said that for many multinational companies, China is not only an important market but also a key part of the global supply chain and innovation chain.
In his view, the competitive advantages of Chinese companies are also continuously evolving. Beyond efficiency and cost advantages, Chinese companies excel in creativity, business acumen, and “last mile” innovation that closely meets market demands. Meanwhile, the combination of a complete industrial chain and China’s “speed” further amplifies their comprehensive advantages in R&D, manufacturing, and market responsiveness.
Dai mentioned that there is a huge potential demand in China’s service sector, including healthcare and elderly care, which presents significant opportunities. China’s next “DeepSeek moment” may emerge in the healthcare industry, with the potential to produce globally innovative drugs originating from China.
He believes that as China continues to strengthen innovation-driven development and expand domestic demand, the Chinese market remains highly attractive to multinational companies. To deepen their presence in China, multinational corporations must integrate more deeply into the Chinese market and enhance their adaptability and innovation capabilities. (End)